Development of New Therapeutics for Amyotrophic Lateral Sclerosis
Development of New Therapeutics for Amyotrophic Lateral Sclerosis
批准号:
8134328
负责人:
Robert H. Brown
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-09-01 至 2012-08-31
关键词:
2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazoleAmyotrophic Lateral SclerosisApoptoticBiological AssayBiological FactorsBlood - brain barrier anatomyBrain DiseasesCell DeathCell SurvivalCell modelCellsCessation of lifeChemical StructureDegradation PathwayDetectionDevelopmentDiseaseDisease ProgressionDoseDrug IndustryDrug KineticsDrug usageFDA approvedFluorescenceGlutamate TransporterGlutamatesGoalsHela CellsIn VitroLaboratoriesLeadLibrariesMeasurementMediatingMissionModelingMotorMotor NeuronsMusNational Institute of Neurological Disorders and StrokeNerve DegenerationNeurodegenerative DisordersOrphan DiseasePathologyPharmaceutical ChemistryPharmaceutical PreparationsPhasePreventionPropertyProteinsReporterResearch PersonnelSafetyScreening procedureStrokeStructureSuperoxide DismutaseTargeted ResearchTestingToxic effectToxicologyTransgenic MiceWestern BlottingWild Type MouseWorkbasedrug candidatedrug discoveryhigh throughput screeningluminescencemotor neuron degenerationmouse modelmutantneuron lossnovel therapeuticsprogramspromoterresearch clinical testingresponsesmall moleculespinal cord and brain injuryuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of this project is to identify small molecules that treat amyotrophic lateral sclerosis (ALS), a uniformly lethal, unbeatable neurodegenerative motor neurons disorder. As an orphan disease, ALS has not generally been a research target for the pharmaceutical industry. We therefore believe it is incumbent on academic laboratories to undertake drug discovery programs for molecules that slow or reverse motor neuron pathology in ALS. This proposal endeavors to do this through four projects. Each is based on an existing in vitro cell model that recapitulates key pathobiological features of ALS. These models screen for compounds that (1) inhibit cell death induced by mutant superoxide dismutase (mSOD1); (2) down-regulate expression of mSOD1; (3) enhance glutamate transport by the major astroglial glutamate transporter EAAT2; and (4) accelerate degradation of mS01 protein. Each cell-based model is fully operational in high throughput screens that represent the initial step of our working strategy. The four projects are divided into two sequential phases as follows: Early phase: Aim 1 Perform high throughput screens (HTS) using a library (MIND library) of 38,500 compounds; Aim 2 Perform secondary, low throughput screening (LTS) assays to validate HTS hits and perform in vitro toxicology and dose response studies; Aim 3 Optimize the chemical structure of positive compounds using structure activity studies and/or medicinal chemistry. Late phase: Aim 4 Evaluate the lead compounds for pharmacokinetic (permeation of the blood brain barrier) and safety properties; and Aim 5 Determine the efficacy of the lead compound(s) in ameliorating motor neuron degeneration in a transgenic mouse model of ALS. In our view, this project is highly relevant to the mission of the NINDS. Small molecules therapies for motor neuron degeneration are likely to be beneficial not only in ALS but also in other neurodegenerative disorders and potentially in conditions such as stroke or traumatic brain and spinal cord injury. Lay Summary: This is a proposal to discover drugs to treat Lou Gehrig's disease, a lethal disorder that is largely ignored by most drug companies; drugs identified in this program may help other brain diseases.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models.
筛选 SOD1 基因启动子抑制剂:乙胺嘧啶不会降低细胞和动物模型中的 SOD1 水平。
DOI:
10.1016/j.neulet.2010.07.020
发表时间:
2010
期刊:
Neuroscience letters
影响因子:
2.5
作者:
[Wright,PaulD, Huang,Mickey, Weiss,Alexandra, Matthews,Jonathan, Wightman,Nicholas, Glicksman,Marcie, BrownJr,RobertH]
通讯作者:
BrownJr,RobertH
DOI:
10.2741/e584
发表时间:
2012-06-01
期刊:
Frontiers in bioscience (Elite edition)
影响因子:
--
作者:
[Wright PD, Wightman N, Huang M, Weiss A, Sapp PC, Cuny GD, Ivinson AJ, Glicksman MA, Ferrante RJ, Matson W, Matson S, Brown RH Jr]
通讯作者:
Brown RH Jr
Next-generation antisense therapeutics for ALS and frontotemporal dementia
-
批准号:10599901
-
项目类别:
-
资助金额:$63.51万
-
财政年份:2019
-
负责人:Robert H. Brown
-
依托单位:
Next-generation antisense therapeutics for ALS and frontotemporal dementia
-
批准号:9765950
-
项目类别:
-
资助金额:$66.04万
-
财政年份:2019
-
负责人:Robert H. Brown
-
依托单位:
Next-generation antisense therapeutics for ALS and frontotemporal dementia
-
批准号:10374767
-
项目类别:
-
资助金额:$63.51万
-
财政年份:2019
-
负责人:Robert H. Brown
-
依托单位:
Next-generation antisense therapeutics for ALS and frontotemporal dementia
-
批准号:9924676
-
项目类别:
-
资助金额:$63.51万
-
财政年份:2019
-
负责人:Robert H. Brown
-
依托单位:
Silencing C9or72 with rAAV Mediated RNAi
-
批准号:8767751
-
项目类别:
-
资助金额:$37.74万
-
财政年份:2014
-
负责人:Robert H. Brown
-
依托单位:
Silencing C9or72 with rAAV Mediated RNAi
-
批准号:9042441
-
项目类别:
-
资助金额:$36.05万
-
财政年份:2014
-
负责人:Robert H. Brown
-
依托单位:
Silencing C9or72 with rAAV Mediated RNAi
-
批准号:8853963
-
项目类别:
-
资助金额:$36.05万
-
财政年份:2014
-
负责人:Robert H. Brown
-
依托单位:
Silencing C9or72 with rAAV Mediated RNAi
-
批准号:9267549
-
项目类别:
-
资助金额:$46.41万
-
财政年份:2014
-
负责人:Robert H. Brown
-
依托单位:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
-
批准号:8500486
-
项目类别:
-
资助金额:$47.9万
-
财政年份:2012
-
负责人:Robert H. Brown
-
依托单位:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
-
批准号:8348533
-
项目类别:
-
资助金额:$53.91万
-
财政年份:2012
-
负责人:Robert H. Brown
-
依托单位:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
-
批准号:8640222
-
项目类别:
-
资助金额:$48.58万
-
财政年份:2012
-
负责人:Robert H. Brown
-
依托单位:
High Throughput Screening for Compounds to Mitigate Toxicity of FUS/TLS & SOD1
-
批准号:8830481
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2012
-
负责人:Robert H. Brown
-
依托单位:
Transgenic Mouse Models of FUS/TLS-Mediated Amyotrophic Lateral Sclerosis
-
批准号:7821236
-
项目类别:
-
资助金额:$49.99万
-
财政年份:2009
-
负责人:Robert H. Brown
-
依托单位:
Transgenic Mouse Models of FUS/TLS-Mediated Amyotrophic Lateral Sclerosis
-
批准号:7937835
-
项目类别:
-
资助金额:$49.97万
-
财政年份:2009
-
负责人:Robert H. Brown
-
依托单位:
Full Human Genome Sequencing in ALS
-
批准号:7855558
-
项目类别:
-
资助金额:$180.44万
-
财政年份:2009
-
负责人:Robert H. Brown
-
依托单位:
Full Human Genome Sequencing in ALS
-
批准号:7939625
-
项目类别:
-
资助金额:$180.39万
-
财政年份:2009
-
负责人:Robert H. Brown
-
依托单位:
CLINICAL TRIAL: PYRIMETHAMINE FOR TREATMENT OF SOD1 MEDIATED AMYLOTROPHIC LATERA
-
批准号:7731272
-
项目类别:
-
资助金额:$0.16万
-
财政年份:2008
-
负责人:Robert H. Brown
-
依托单位:
Development of New Therapeutics for Amyotrophic Lateral Sclerosis
-
批准号:7944010
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2007
-
负责人:Robert H. Brown
-
依托单位:
Development of New Therapeutics for Amyotrophic Lateral Sclerosis
-
批准号:7488977
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2007
-
负责人:Robert H. Brown
-
依托单位:
Development of New Therapeutics for Amyotrophic Lateral Sclerosis
-
批准号:7208427
-
项目类别:
-
资助金额:$76.09万
-
财政年份:2007
-
负责人:Robert H. Brown
-
依托单位:
海外基金